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Introduction {#jah31516-sec-0004}
============

Several large, randomized, clinical trials[1](#jah31516-bib-0001){ref-type="ref"}, [2](#jah31516-bib-0002){ref-type="ref"}, [3](#jah31516-bib-0003){ref-type="ref"} and Mendelian randomization studies[4](#jah31516-bib-0004){ref-type="ref"} have failed to show a causal role for high‐density lipoprotein cholesterol (HDL‐C) levels in cardioprotection, decreasing interest in HDL as a therapeutic target. However, recent work from the Multi Ethnic Study of Atherosclerosis (MESA) found that total HDL particle concentration (HDL‐P) measured by nuclear magnetic resonance (NMR) spectroscopy is a significant predictor of incident cardiovascular events and carotid intima‐media thickening (cIMT), even when adjusting for the effects of HDL‐C and other cardiovascular disease (CVD) confounders.[5](#jah31516-bib-0005){ref-type="ref"} Other recent work in MESA has found that the combination of small and medium HDL‐P concentration was an independent predictor for noncardiovascular inflammation‐related death/hospitalization and, separately, incident coronary heart disease events.[6](#jah31516-bib-0006){ref-type="ref"} These studies suggested that unmeasured aspects of HDL not reflected by HDL‐C (such as antioxidant and anti‐inflammatory properties[6](#jah31516-bib-0006){ref-type="ref"}) might be responsible for the long‐held and consistent cardioprotective associations of HDL.[7](#jah31516-bib-0007){ref-type="ref"}

The HDL particle is a heterogeneous molecule with over 70 associated proteins.[8](#jah31516-bib-0008){ref-type="ref"} Broadly, HDL can be distinguished into two subfractions by density: HDL2 and HDL3. Unlike HDL3, HDL2 is larger, less dense, and strongly associated with apolipoprotein A1 (apoA1). HDL2 carries the majority of cholesterol reflected in HDL‐C measurements.[9](#jah31516-bib-0009){ref-type="ref"} On the other hand, HDL3 carries enzymes that prevent oxidative stress[10](#jah31516-bib-0010){ref-type="ref"} and receives cholesterol from reverse cholesterol transport through the ATP‐binding cassette transporter A1 (ABCA1) mediators.[11](#jah31516-bib-0011){ref-type="ref"} We have previously demonstrated that HDL3 cholesterol (HDL3‐C) is well approximated by the sum of small and medium HDL‐P concentration, whereas HDL2 cholesterol (HDL2‐C) correlates strongly with large HDL‐P concentration.[12](#jah31516-bib-0012){ref-type="ref"}, [13](#jah31516-bib-0013){ref-type="ref"}

Previous work by Kontush and Chapman has established the hypothesis that smaller and denser HDL‐P are the source of overall HDL cardioprotection.[14](#jah31516-bib-0014){ref-type="ref"}, [15](#jah31516-bib-0015){ref-type="ref"}, [16](#jah31516-bib-0016){ref-type="ref"} Several functions have been proposed for this observation of small and dense HDL\'s cardioprotection: its ability to accept cholesterol from foam cells by ABCA1,[17](#jah31516-bib-0017){ref-type="ref"} antioxidant activity,[10](#jah31516-bib-0010){ref-type="ref"} antiapoptotic actions,[18](#jah31516-bib-0018){ref-type="ref"}, [19](#jah31516-bib-0019){ref-type="ref"} and its anti‐inflammatory properties,[20](#jah31516-bib-0020){ref-type="ref"} among other hypotheses previously reviewed in detail.[15](#jah31516-bib-0015){ref-type="ref"}, [21](#jah31516-bib-0021){ref-type="ref"}

To investigate whether one of these unmeasured functional aspects of HDL associated with HDL2 or HDL3 were responsible for the cardioprotective effects of HDL, we previously performed analyses to determine whether HDL‐C, HDL2‐C, HDL3‐C, or apoA1 was the best predictor of carotid artery disease status.[22](#jah31516-bib-0022){ref-type="ref"} In that work, the smaller HDL3‐C subfraction cholesterol was found to be the best predictor of reduced odds of carotid artery disease, demonstrating the utility of the HDL3‐C measure versus HDL‐C.[22](#jah31516-bib-0022){ref-type="ref"} Follow‐up work in a subset of this carotid artery disease case‐control study found that differences in small and medium HDL‐P concentration were the primary determinants of HDL‐P concentration differences between cases and controls.[13](#jah31516-bib-0013){ref-type="ref"} In a separate study of ≈1000 stroke‐free subjects, HDL3‐C was negatively associated with carotid plaque area, whereas HDL2‐C was positively associated.[23](#jah31516-bib-0023){ref-type="ref"} These results support the aforementioned hypothesis that cholesterol‐poor HDL subspecies, which are under‐represented in measures of HDL‐C, may be important protective factors against cerebrovascular disease.[14](#jah31516-bib-0014){ref-type="ref"}, [15](#jah31516-bib-0015){ref-type="ref"}, [16](#jah31516-bib-0016){ref-type="ref"}

Given these findings, we sought to validate the association of HDL3‐C with cIMT in an independent cohort. Because HDL3‐C is closely approximated by the sum of small and medium HDL‐P concentration (small+medium HDL‐P), our primary goal in the present study was to determine whether small+medium HDL‐P concentration was associated with decreased common and internal cIMT in a cross‐sectional analysis of MESA participants. We note that the combination of small+medium HDL‐P has been used in several other studies as a measure of small, dense, and potentially cardioprotective HDL.[6](#jah31516-bib-0006){ref-type="ref"}, [24](#jah31516-bib-0024){ref-type="ref"} We simultaneously sought to evaluate whether large HDL‐P concentration was similarly cardioprotective in cross‐sectional analyses after covariate adjustment. Finally, as a follow‐up analysis, we evaluated the correlation between the HDL‐P subspecies as measured by ion mobility and paraoxonase 1 (PON1) activity, which has previously been reported as protective against carotid artery disease[25](#jah31516-bib-0025){ref-type="ref"}, [26](#jah31516-bib-0026){ref-type="ref"}, [27](#jah31516-bib-0027){ref-type="ref"}, [28](#jah31516-bib-0028){ref-type="ref"} in the Seattle‐based CLEAR study. Notably, ion mobility was developed subsequent to NMR spectroscopy measurement of HDL‐P and provides similar, though not identical, estimates.[13](#jah31516-bib-0013){ref-type="ref"} The MESA cohort did not have these PON1 activity data available.

Methods {#jah31516-sec-0005}
=======

Ethics Statement {#jah31516-sec-0006}
----------------

Informed, written consent was obtained from each participant of MESA at the time of recruitment between July 2000 and August 2002. Institutional review boards at each participating center of MESA approved of the study. The University of Washington Institutional Review Board approved analyses presented in this work.

MESA Cohort Sample {#jah31516-sec-0007}
------------------

MESA is a multicenter, longitudinal cohort study of the prevalence and progression of subclinical atherosclerotic disease phenotypes. Between July 2000 and August 2002, MESA recruited 6814 participants between 45 and 84 years of age from 6 field sites: Baltimore City and Baltimore County, Maryland; Chicago, Illinois; Forsyth County, North Carolina; Los Angeles County, California; northern Manhattan and the Bronx, New York; and St Paul, Minnesota. Participants were of African‐American, Hispanic, white, and Chinese‐American self‐reported ancestry. Baseline exclusion criteria for recruitment were: self‐reported CVD history, pregnancy, cancer, cognitive impairment, or weight \>136 kg. At the time of recruitment, each participant underwent examination, including blood draw, anthropometric measurements, and collection of questionnaire data.

Lipid Measurements {#jah31516-sec-0008}
------------------

In MESA, all lipid and covariate data were collected at physical examination during study enrollment. Blood was drawn after a 12‐h fast, and samples were stored at −70°C with EDTA. Plasma HDL‐P concentration was measured at LipoScience, Inc. (Raleigh, NC) using NMR spectroscopy and the LipoProfile‐3 algorithm.[29](#jah31516-bib-0029){ref-type="ref"}, [30](#jah31516-bib-0030){ref-type="ref"} All other lipids and fasting glucose were measured at a separate central laboratory (Collaborative Studies Clinical Laboratory at Fairview University Medical Center, Minneapolis, MN). HDL‐C was measured after precipitation of non‐HDL cholesterol through exposure to magnesium/dextran, using the cholesterol oxidase method (Roche Diagnostics, Indianapolis, IN). LDL‐C was calculated using the Friedwahl equation.[31](#jah31516-bib-0031){ref-type="ref"} The sum of small and medium HDL‐P measures (small+medium HDL‐P) was used as a proxy variable for HDL3‐C,[12](#jah31516-bib-0012){ref-type="ref"}, [13](#jah31516-bib-0013){ref-type="ref"} because we previously have found HDL3‐C to be protective against carotid artery disease.[22](#jah31516-bib-0022){ref-type="ref"}

Covariates {#jah31516-sec-0009}
----------

Demographic information such as body mass index (BMI), blood pressure, smoking history, and medication use were all collected at the baseline MESA physical examination. Smoking was defined as never, former (smoked ≥100 cigarettes in a lifetime), or current. Pack‐years of smoking were also calculated from this survey information. Fasting glucose was measured after an overnight fast. Diabetes status was defined as a fasting glucose ≥126 mg/dL or use of an antidiabetic medication. Systolic blood pressure (SBP) was measured at rest from the brachial artery with the participant in a sitting position. Antihypertensive medication (HTN Rx) and lipid‐lowering medication use (LLM Rx) were determined by self‐report at the baseline MESA examination.

cIMT Measurement {#jah31516-sec-0010}
----------------

High‐resolution B‐mode ultrasound was used to measure carotid atherosclerosis as previously described.[32](#jah31516-bib-0032){ref-type="ref"} Total cIMT in micrometers (μm) was calculated separately from maximal carotid artery thickening at 4 sites (right and left; near and far walls) for the common and internal carotid arteries, respectively.[33](#jah31516-bib-0033){ref-type="ref"}

Carotid Lesion Epidemiology And Risk Study Sample {#jah31516-sec-0011}
-------------------------------------------------

The Carotid Lesion Epidemiology And Risk (CLEAR) study is a Seattle‐based prevalent carotid artery disease case‐control study, comprised primarily of veterans, with controls distribution matched by sex and age at diagnosis of carotid artery disease cases. Exclusion criteria for the CLEAR study included familial hypercholesterolemia, total fasting cholesterol \>400 mg/dL, hypocoagulable state or use of hypocoagulant medication, postorgan transplant, or inability to consent. Diabetes status was defined as hemoglobin A1c ≥6.5% or use of oral hypoglycemic therapy or insulin. Medication use was determined by self‐report and then matched to pharmacy records. We previously have reported a carotid artery disease--protective effect of small+medium HDL‐P concentration and HDL3 in CLEAR.[13](#jah31516-bib-0013){ref-type="ref"}, [22](#jah31516-bib-0022){ref-type="ref"} The analyzed subset of CLEAR described here is composed of 126 men without CVD not on statin pharmacotherapy.

Standard methods were used in the CLEAR study to determine plasma levels of total cholesterol, triglycerides, very low‐density lipoprotein cholesterol, and HDL‐C using an Abbott Spectrum analyzer (Abbott Laboratories, Abbott Park, IL). All samples were analyzed at a central laboratory, the Northwest Lipid Research Laboratory, and used fasting plasma stored with lithium heparin. In the CLEAR study, PON1 enzyme activity was measured by rate of enzymatic degradation of phenylacetate (AREase) by a continuous spectrophotometric assay with lithium heparin plasma as previously described.[25](#jah31516-bib-0025){ref-type="ref"}, [26](#jah31516-bib-0026){ref-type="ref"}, [27](#jah31516-bib-0027){ref-type="ref"} PON1 AREase activity had an approximate normal distribution. HDL‐P was measured using calibrated ion mobility analysis, as previously described.[13](#jah31516-bib-0013){ref-type="ref"} This ion mobility method of determining HDL‐P is expected to deliver closely correlated, but distinct measurements of HDL‐P as compared to NMR,[13](#jah31516-bib-0013){ref-type="ref"} which was used in MESA.

Statistical Analysis {#jah31516-sec-0012}
--------------------

All analyses and graphics were performed in R software (<http://r-project.org>). For our primary analyses, the outcomes of total common and internal cIMT were separately analyzed for association with either the sum of small+medium HDL‐P or large HDL‐P concentrations. We used a linear regression model adjusting for the confounders of age, sex, race (coded as a dummy variable with whites, the largest subgroup, as the reference group and blacks, Hispanics, and Asians as the comparison groups), BMI, cigarette smoking status (former or current, with the never group as reference), pack‐years of smoking, SBP, antihypertensive medication use, fasting glucose, diabetes status, LLM Rx use, LDL‐C, and HDL‐C. A Bonferroni‐corrected threshold of significance of 0.0125 (α=0.05/4) was applied because of the 4 tests in our primary hypothesis: common cIMT with small+medium HDL‐P and large HDL‐P and internal cIMT with small+medium HDL‐P and large HDL‐P.

To aid in interpretation, we present results in a staged regression model, adjusting first for demographic (age, sex, and race), then adding cardiovascular risk factors (BMI, cigarette smoking status, pack‐years of smoking, SBP, HTN Rx, fasting glucose, diabetes status, and LLM Rx), subsequently adding LDL‐C, and finally adding HDL‐C to the linear regression model. We note that staged regression models were not used in the primary analyses, but are presented in table form to illustrate the effect of HDL‐C on the association of small+medium HDL‐P versus large HDL‐P on the cIMT outcomes.

To illustrate multivariable regression results, we separately plotted covariate‐adjusted mean internal and common cIMT for quartiles of small+medium HDL‐P and large HDL‐P, respectively. Two lines are presented in each plot: one for covariate‐adjusted internal or common cIMT with all covariates except HDL‐C in the model and a second line with all covariates in the final regression model.

Sensitivity analyses were performed by race group and sex for the association of small+medium HDL‐P with both common and internal cIMT. Significant differences in association of small+medium HDL‐P with either outcome were followed‐up with addition of a formal interaction term to the regression model (eg, sex×small+medium HDL‐P). Presence of effect modification was concluded if the interaction term was significantly different than zero (*P*≤0.05).

Results {#jah31516-sec-0013}
=======

MESA participants analyzed in this work were multiethnic men and women without baseline CVD with a mean age of 62.2 years (see Table [1](#jah31516-tbl-0001){ref-type="table-wrap"}). Men composed 47.2% of the study population. Self‐reported whites were the largest ethnic group, representing 38.5% of the participants, followed by blacks (27.8%), Hispanics (21.9%), and Asians (11.8%). Common and internal artery cIMT had means of 870.51 and 1071.52 μm, respectively. Baseline clinical and demographic characteristics of the MESA participants are summarized in Table [1](#jah31516-tbl-0001){ref-type="table-wrap"}. Correlations of demographic, lipid, and clinical variables with small, medium, large, and small+medium HDL‐P have been reported recently by Duprez et al. in a largely overlapping data set from MESA.[6](#jah31516-bib-0006){ref-type="ref"}

###### 

Baseline Multi Ethnic Study of Atherosclerosis (MESA) Cohort Demographic and Clinical Characteristics

                                   N      Mean (±SD) or N (%)
  -------------------------------- ------ ---------------------
  Age, y                           6814   62.2 (±10.2)
  Race                             6814   
  White, %                                2622 (38.5)
  Asian, %                                804 (11.8)
  Black, %                                1892 (27.8)
  Hispanic, %                             1496 (21.9)
  Men, %                           6814   3213 (47.2)
  Body mass index, kg/m^2^         6814   28.3 (±5.48)
  Smoking status                   6792   
  Never, %                                3418 (50.3)
  Former, %                               2487 (33.6)
  Current, %                              887 (13.1)
  Cigarette pack‐years             6720   11.3 (±20.9)
  Systolic blood pressure, mm Hg   6811   126.6 (±21.5)
  Antihypertensive Rx, %           6811   2536 (37.2)
  Fasting glucose, mg/dL           6789   104.5 (±30.9)
  Diabetes status, %               6814   859 (12.6)
  Lipid‐lowering Rx, %             6811   1100 (16.2)
  LDL‐C, mg/dL                     6701   117.2 (±31.5)
  HDL‐C, mg/dL                     6701   50.9 (±14.8)
  Triglycerides, mg/dL             6786   135.1 (±68.9)
  Large HDL‐P, μmol/L              6786   6.02 (±3.46)
  Small+medium HDL‐P, μmol/L       6786   28.01 (±5.48)
  Small HDL‐P, μmol/L              6786   13.27 (±6.84)
  Medium HDL‐P, μmol/L             6786   14.74 (±5.73)
  Common cIMT, μm                  6726   870.51 (±193.43)
  Internal cIMT, μm                6629   1071.52 (±603.44)

cIMT indicates carotid intima‐media thickening; HDL‐C, high‐density lipoprotein cholesterol; HDL‐P, high‐density lipoprotein particle concentration; LDL‐C, low‐density lipoprotein cholesterol; Rx, medication.

After full adjustment (including LDL‐C and HDL‐C), small+medium HDL‐P concentration was significantly and inversely associated common cIMT at a Bonferroni‐corrected threshold of α=0.0125 (*P*=0.00037; see Table [2](#jah31516-tbl-0002){ref-type="table-wrap"}), with a final covariate‐adjusted beta coefficient of −1.46 μm. In contrast, after full adjustment (including LDL‐C and HDL‐C), large HDL‐P concentration was not significantly associated with common cIMT (*P*=0.30).

###### 

Staged Linear Regression Model Association of Small+Medium HDL‐P and Large HDL‐P Concentration With Carotid Intima‐Media Thickening (μm) in the Common Carotid Arteries (n=6512)

                                                                        Small+Medium HDL‐P, μmol/L   Large HDL‐P, μmol/L                
  --------------------------------------------------------------------- ---------------------------- --------------------- ------------ ----------
  Small+medium HDL‐P or large HDL‐P, unadjusted                         −1.63±0.43                   0.00024               −4.15±0.69   \<0.0001
  +Demographic characteristics[a](#jah31516-note-0003){ref-type="fn"}   −0.95±0.41                   0.019                 −5.45±0.67   \<0.0001
  +Above and CVD risk factors[b](#jah31516-note-0004){ref-type="fn"}    −1.94±0.40                   \<0.0001              −2.95±0.69   \<0.0001
  +Above and LDL‐C                                                      −1.76±0.39                   \<0.0001              −2.28±0.69   0.0011
  +Above and HDL‐C                                                      −1.46±0.41                   0.00037               1.55±1.50    0.30

Final regression model coefficients/*P* values for association with internal cIMT are available in Tables [4](#jah31516-tbl-0004){ref-type="table-wrap"} (small+medium HDL‐P) and [5](#jah31516-tbl-0005){ref-type="table-wrap"} (large HDL‐P). cIMT indicates carotid intima‐media thickening; HDL‐C, high‐density lipoprotein cholesterol; HDL‐P, high‐density lipoprotein particle concentration; LDL‐C, low‐density lipoprotein cholesterol.

Demographic characteristics are defined as age, sex, and race (Asian, black, or Hispanic, with white as the reference group).

Cardiovascular disease (CVD) risk factors defined as body mass index, cigarette smoking status (former or current, with never group as reference), pack‐years of smoking, systolic blood pressure, antihypertensive medication, fasting glucose, diabetes status, and lipid‐lowering medication use.

A similar pattern was observed for associations with internal cIMT. After full adjustment, small+medium HDL‐P concentration was significantly and inversely associated at a Bonferroni‐corrected threshold of α=0.0125 with internal cIMT (*P*=0.0051; beta coefficient=−3.82 μm; see Table [3](#jah31516-tbl-0003){ref-type="table-wrap"}). In contrast, after full adjustment, large HDL‐P concentration was not significantly associated with internal cIMT (*P*=0.33). Full regression coefficients for all covariates are presented in Table [4](#jah31516-tbl-0004){ref-type="table-wrap"} for small+medium HDL‐P and both common and internal cIMT, and separately in Table [5](#jah31516-tbl-0005){ref-type="table-wrap"} for large HDL‐P with both common and internal IMT.

###### 

Staged Linear Regression Model Association of Small+Medium HDL‐P and Large HDL‐P Concentration With Carotid Intima‐Media Thickening (μm) in the Internal Carotid Arteries (n=6418)

                                                                        Small+Medium HDL‐P, μmol/L   Large HDL‐P, μmol/L                 
  --------------------------------------------------------------------- ---------------------------- --------------------- ------------- ----------
  Small+medium HDL‐P or large HDL‐P, unadjusted                         −2.88±1.38                   0.037                 −10.91±2.18   \<0.0001
  +Demographic characteristics[a](#jah31516-note-0006){ref-type="fn"}   −2.15±1.34                   0.11                  −12.17±2.22   \<0.0001
  +Above and CVD risk factors[b](#jah31516-note-0007){ref-type="fn"}    −4.91±1.33                   0.00036               −6.36±2.28    0.0054
  +Above and LDL‐C                                                      −4.45±1.33                   0.00081               −4.62±2.31    0.045
  +Above and HDL‐C                                                      −3.82±1.36                   0.0051                4.84±4.99     0.33

Final regression model coefficients/*P* values for association with internal cIMT are available in Tables [4](#jah31516-tbl-0004){ref-type="table-wrap"} (small+medium HDL‐P) and [5](#jah31516-tbl-0005){ref-type="table-wrap"} (large HDL‐P). cIMT indicates carotid intima‐media thickening; HDL‐C, high‐density lipoprotein cholesterol; HDL‐P, high‐density lipoprotein particle concentration; LDL‐C, low‐density lipoprotein cholesterol.

Demographic characteristics are defined as age, sex, and race (Asian, black, or Hispanic, with white as the reference group).

Cardiovascular disease (CVD) risk factors defined as body mass index, cigarette smoking status (former or current, with never group as reference), pack‐years of smoking, systolic blood pressure, antihypertensive medication, fasting glucose, diabetes status, and lipid‐lowering medication use.

###### 

Full Multivariable Regression Model Coefficients for Association of Small+Medium HDL‐P and Common cIMT and Internal cIMT

  Covariates                   Common cIMT, μm (N=6512)                            Internal cIMT, μm (N=6418)                                                                           
  ---------------------------- --------------------------------------------------- ------------------------------------------------ --------------------------------------------------- -----------------------------------------------
  Age, y                       7.11±0.23                                           \<0.0001                                         15.79±0.76                                          \<0.0001
  Black, %                     20.48±5.44                                          0.00017                                          −60.70±18.11                                        0.00081
  Hispanic, %                  −13.39±5.71                                         0.019                                            −73.96±18.98                                        \<0.0001
  Asian, %                     −25.12±7.13                                         0.00043                                          −205.88±23.72                                       \<0.0001
  Male sex, %                  33.25±4.67                                          \<0.0001                                         80.29±15.55                                         \<0.0001
  BMI, kg/m^2^                 3.05±0.44                                           \<0.0001                                         1.73±1.47                                           0.24
  Former smoker, %             11.35±5.24                                          0.030                                            47.69±17.44                                         0.0063
  Current smoker, %            5.23±7.37                                           0.48                                             96.79±24.51                                         \<0.0001
  Pack‐years                   0.46±0.12                                           0.00013                                          2.49±0.40                                           \<0.0001
  SBP, mm Hg                   1.52±0.11                                           \<0.0001                                         2.71±0.36                                           \<0.0001
  HTN Rx, %                    4.06±4.77                                           0.39                                             70.25±15.86                                         \<0.0001
  Fasting glucose, mg/dL       0.17±0.094                                          0.079                                            0.50±0.31                                           0.11
  Diabetes status, %           20.47±8.70                                          0.019                                            84.21±28.96                                         0.0037
  LDL‐C, mg/dL                 0.42±0.067                                          \<0.0001                                         1.08±0.22                                           \<0.0001
  HDL‐C, mg/dL                 −0.54±0.16                                          0.00086                                          −1.12±0.54                                          0.039
  LLM Rx, %                    20.28±5.87                                          0.00055                                          135.40±19.52                                        \<0.0001
  Small+medium HDL‐P, μmol/L   −1.46±0.41[a](#jah31516-note-0009){ref-type="fn"}   0.00037[a](#jah31516-note-0009){ref-type="fn"}   −3.82±1.36[b](#jah31516-note-0010){ref-type="fn"}   0.0051[b](#jah31516-note-0010){ref-type="fn"}

BMI indicates body mass index; cIMT, carotid intima‐media thickening; HDL‐C, high‐density lipoprotein cholesterol; HDL‐P, high‐density lipoprotein particle concentration; HTN Rx, hypertension medication treatment; LDL‐C, low‐density lipoprotein cholesterol; LLM Rx, lipid‐lowering medication treatment; SBP, systolic blood pressure.

When modeling small and medium HDL‐P separately (rather than the sum of small+medium HDL‐P) with common cIMT, small HDL‐P has a beta coefficient of −1.35 and *P*=0.0052 whereas medium HDL‐P has a beta coefficient of −1.52 and a *P*=0.00054.

When modeling small and medium HDL‐P separately (rather than the sum of small+medium HDL‐P) with internal cIMT, small HDL‐P has a beta coefficient of −4.44 and *P*=0.0059 whereas medium HDL‐P has a beta coefficient of −3.44 and a *P*=0.019.

###### 

Full Multivariable Regression Model Coefficients for Association of Large HDL‐P and Common cIMT and Internal cIMT

  Covariates               Common cIMT, μm (N=6512)   Internal cIMT, μm (N=6418)                   
  ------------------------ -------------------------- ---------------------------- --------------- ----------
  Age, y                   7.12±0.23                  \<0.0001                     15.80±0.76      \<0.0001
  Black, %                 23.32±5.39                 \<0.0001                     −53.58±17.94    0.0028
  Hispanic, %              −12.59±5.72                0.028                        −72.13±19.03    0.00015
  Asian, %                 −24.79±7.16                0.00054                      −205.34±23.81   \<0.0001
  Male sex, %              36.47±4.466                \<0.0001                     89.04±15.49     \<0.0001
  BMI, kg/m^2^             2.97±0.44                  \<0.0001                     1.53±1.47       0.29
  Former smoker, %         11.01±5.25                 0.036                        46.87±17.45     0.0073
  Current smoker, %        5.43±7.37                  0.46                         97.39±24.52     \<0.0001
  Pack‐years               0.46±0.12                  0.00013                      2.49±0.40       \<0.0001
  SBP, mm Hg               1.49±0.11                  \<0.0001                     2.62±0.36       \<0.0001
  HTN Rx, %                3.77±4.77                  0.43                         69.53±15.87     \<0.0001
  Fasting glucose, mg/dL   0.15±0.094                 0.11                         0.47±0.31       0.14
  Diabetes status, %       21.56±8.71                 0.013                        87.07±28.95     0.0026
  LDL‐C, mg/dL             0.45±0.068                 \<0.0001                     1.16±0.23       \<0.0001
  HDL‐C, mg/dL             −0.99±0.34                 0.0040                       −2.45±1.15      0.032
  LLM Rx, %                18.50±5.85                 0.0016                       130.95±19.47    \<0.0001
  Large HDL‐P, μmol/L      1.55±1.50                  0.30                         4.84±4.99       0.33

BMI indicates body mass index; cIMT, carotid intima‐media thickening; HDL‐C, high‐density lipoprotein cholesterol; HDL‐P, high‐density lipoprotein particle concentration; HTN Rx, hypertension medication treatment; LDL‐C, low‐density lipoprotein cholesterol; LLM Rx, lipid‐lowering medication treatment; SBP, systolic blood pressure.

Notably, in post‐hoc analyses, large HDL‐P was strongly and inversely associated with common and internal cIMT after adjustment for demographic covariates, CVD risk factors, and LDL‐C. However, addition of HDL‐C caused both of these associations to attenuate and become nonsignificant (see Tables [2](#jah31516-tbl-0002){ref-type="table-wrap"} and [3](#jah31516-tbl-0003){ref-type="table-wrap"}). Moreover, in final regression models including HDL‐C, the direction of effect for large HDL‐P indicated that increasing levels of large HDL‐P was associated with increased common (beta coefficient=1.55 μm; *P*=0.30) and internal (beta coefficient=4.84 μm; *P*=0.31) cIMT. In contrast, the inverse association of small+medium HDL‐P with both common and internal cIMT remained robust even after the addition of HDL‐C to the model (see Tables [2](#jah31516-tbl-0002){ref-type="table-wrap"} and [3](#jah31516-tbl-0003){ref-type="table-wrap"}). Graphical representations of the effect of HDL‐C on regression model prediction of common and internal cIMT are presented in Figures [1](#jah31516-fig-0001){ref-type="fig"} and [2](#jah31516-fig-0002){ref-type="fig"}, respectively, for both small+medium and large HDL‐P.

![Mean covariate‐adjusted common cIMT (μm) for small+medium high‐density lipoprotein particle concentration (HDL‐P) (A) and large HDL‐P (B) before and after adjustment for HDL‐C. See Tables [4](#jah31516-tbl-0004){ref-type="table-wrap"} and [5](#jah31516-tbl-0005){ref-type="table-wrap"} for list of covariates. cIMT indicates carotid intima‐media thickening; HDL‐C, high‐density lipoprotein cholesterol.](JAH3-5-e002977-g001){#jah31516-fig-0001}

![Mean covariate‐adjusted internal cIMT (μm) for small+medium high‐density lipoprotein particle concentration (HDL‐P) (A) and large HDL‐P (B) before and after adjustment for HDL‐C. See Tables [4](#jah31516-tbl-0004){ref-type="table-wrap"} and [5](#jah31516-tbl-0005){ref-type="table-wrap"} for list of covariates. cIMT indicates carotid intima‐media thickening; HDL‐C, high‐density lipoprotein cholesterol.](JAH3-5-e002977-g002){#jah31516-fig-0002}

To examine the possibility of either small or medium HDL‐P driving the association of small+medium HDL‐P and both cIMT measures, a separate multivariable linear regression model was fit (see footnote of Table [4](#jah31516-tbl-0004){ref-type="table-wrap"}). Both small HDL‐P (beta coefficient=−1.35 μm; *P*=0.0052) and medium HDL‐P (beta coefficient=−1.52 μm, *P*=0.00054) were separately and significantly associated with decreased common cIMT. Small HDL‐P was significantly associated with decreased internal cIMT (beta coefficient=−4.44 μm; *P*=0.0059). Medium HDL‐P was also associated with internal cIMT (beta coefficient=−3.44 μm; *P*=0.019).

Sensitivity analyses were performed for the association of small+medium HDL‐P with common cIMT (Table [6](#jah31516-tbl-0006){ref-type="table-wrap"}) and internal cIMT (Table [7](#jah31516-tbl-0007){ref-type="table-wrap"}) across racial groups. Notably, after full adjustment, small+medium HDL‐P concentration was consistently associated with decreased common and internal cIMT for whites (n=2506; beta coefficient=−1.15 μm and *P*=0.079 with common cIMT and n=2470; beta coefficient=−5.59 μm and *P*=0.013 with internal cIMT) and blacks (n=1808; beta coefficient=−2.15 μm and *P*=0.0058 with common cIMT and n=1782; beta coefficient=−4.11 μm and *P*=0.10 with internal cIMT; see Tables [6](#jah31516-tbl-0006){ref-type="table-wrap"} and [7](#jah31516-tbl-0007){ref-type="table-wrap"}). In Hispanics, small+medium HDL‐P concentration was associated with decreased common cIMT (n=1430; beta coefficient=−1.84 μm and *P*=0.045; see Table [6](#jah31516-tbl-0006){ref-type="table-wrap"}), but was not associated with internal cIMT (n=1409; beta coefficient=−0.81 μm and *P*=0.79; see Table [7](#jah31516-tbl-0007){ref-type="table-wrap"}). Finally, after full adjustment, small+medium HDL‐P was not associated with either cIMT outcome in Asians (n=768; beta coefficient=−0.23 μm and *P*=0.85 with common cIMT and n=757; beta coefficient=−2.25 μm and *P*=0.51 with internal cIMT; see Tables [6](#jah31516-tbl-0006){ref-type="table-wrap"} and [7](#jah31516-tbl-0007){ref-type="table-wrap"}). Statistical interaction tests of race group and small+medium HDL‐P were conducted on full regression models predicting both common and internal cIMT. No effect modification by race group of the association of HDL‐P was found either common (*P*=0.17) and internal cIMT (*P*=0.94) outcomes.

###### 

Sensitivity Analysis by Race of Association of Small+Medium HDL‐P With Common cIMT (μm)

  Covariates                White (N=2506)   Black (N=1808)   Hispanic (N=1430)   Asian (N=768)                                          
  ------------------------- ---------------- ---------------- ------------------- --------------- ------------- ---------- ------------- ----------
  Age, y                    8.04±0.36        \<0.0001         6.79±0.46           \<0.0001        6.96±0.50     \<0.0001   4.77±0.62     \<0.0001
  Male sex, %               25.65±7.57       0.00072          47.53±9.28          \<0.0001        37.46±10.22   0.00026    15.01±13.44   0.26
  BMI, kg/m^2^              3.46±0.73        \<0.0001         2.44±0.78           0.0018          3.21±0.95     0.00075    5.06±1.85     0.0063
  Former smoker, %          15.34±7.98       0.055            8.70±10.47          0.41            10.53±11.36   0.35       8.52±18.71    0.65
  Current smoker, %         14.75±12.48      0.24             −14.73±13.38        0.27            23.56±14.94   0.11       20.68±27.52   0.45
  Pack‐years                0.38±0.16        0.019            0.55±0.26           0.033           0.29±0.32     0.36       0.93±0.49     0.061
  SBP, mm Hg                1.71±0.18        \<0.0001         1.23±0.20           \<0.0001        1.53±0.23     \<0.0001   1.74±0.29     \<0.0001
  HTN Rx, %                 7.42±7.58        0.33             −3.96±9.05          0.66            17.17±10.58   0.10       −9.33±13.91   0.50
  Fasting glucose, mg/dL    0.22±0.21        0.31             0.18±0.17           0.31            0.051±0.16    0.74       0.36±0.27     0.19
  Diabetes status, %        28.26±18.48      0.13             6.65±14.78          0.65            32.14±16.83   0.056      26.46±23.31   0.26
  LDL‐C, mg/dL              0.33±0.11        0.0039           0.39±0.13           0.0017          0.63±0.14     \<0.0001   0.41±0.19     0.037
  HDL‐C, mg/dL              −0.58±0.26       0.023            −0.64±0.31          0.037           −0.25±0.39    0.52       −0.43±0.49    0.39
  LLM Rx, %                 11.54±8.96       0.19             46.81±11.43         \<0.0001        −8.29±13.73   0.55       34.09±17.19   0.048
  Small+Med HDL‐P, μmol/L   −1.15±0.65       0.079            −2.15±0.78          0.0058          −1.84±0.92    0.045      −0.23±1.19    0.85

Linear regression analyses of small+medium HDL‐P and all other covariates in Table [4](#jah31516-tbl-0004){ref-type="table-wrap"}, association with common cIMT in the Multi‐Ethnic Study of Atherosclerosis (MESA) study, stratified by race. BMI indicates body mass index; cIMT, carotid intima‐media thickening; HDL‐C, high‐density lipoprotein cholesterol; HDL‐P, high‐density lipoprotein particle concentration; HTN Rx, hypertension medication treatment; LDL‐C, low‐density lipoprotein cholesterol; LLM Rx, lipid‐lowering medication treatment; SBP, systolic blood pressure.

###### 

Sensitivity Analysis by Race of Association of Small+Medium HDL‐P With Internal cIMT (μm)

  Covariates                White (N=2470)   Black (N=1782)   Hispanic (N=1409)   Asian (N=757)                                            
  ------------------------- ---------------- ---------------- ------------------- --------------- -------------- ---------- -------------- ----------
  Age, y                    18.48±1.24       \<0.0001         15.47±1.53          \<0.0001        17.12±1.65     \<0.0001   6.69±1.77      0.00017
  Male sex, %               66.34±25.96      0.011            52.03±31.13         0.095           150.34±33.61   \<0.0001   62.58±38.44    0.10
  BMI, kg/m^2^              2.73±2.49        0.27             1.11±2.62           0.67            2.08±3.13      0.51       −4.80±5.29     0.36
  Former smoker, %          21.49±27.38      0.43             99.98±35.10         0.0044          58.23±37.35    0.12       2.27±53.52     0.97
  Current smoker, %         91.29±42.76      0.033            107.16±44.85        0.017           167.97±49.13   0.00065    −22.49±78.73   0.78
  Pack‐years                3.29±0.56        \<0.0001         0.97±0.86           0.26            1.49±1.04      0.15       3.26±1.41      0.021
  SBP, mm Hg                2.89±0.62        \<0.0001         3.81±0.68           \<0.0001        1.99±0.75      0.0077     1.56±0.84      0.062
  HTN Rx, %                 147.90±25.97     \<0.0001         4.48±30.35          0.88            54.97±34.79    0.11       19.39±39.80    0.64
  Fasting glucose, mg/dL    0.41±0.73        0.57             0.042±0.58          0.94            0.079±0.52     0.88       1.77±0.77      0.023
  Diabetes status, %        21.47±63.34      0.73             68.53±49.56         0.17            200.96±55.36   0.00029    98.56±66.69    0.14
  LDL‐C, mg/dL              1.39±0.39        0.00039          0.37±0.43           0.39            1.73±0.45      0.00012    0.73±0.56      0.19
  HDL‐C, mg/dL              −1.18±0.88       0.18             −1.44±1.03          0.16            −0.13±1.28     0.92       −2.01±1.43     0.16
  LLM Rx, %                 118.81±30.70     0.00011          204.28±38.33        \<0.0001        50.03±45.16    0.27       201.14±49.19   \<0.0001
  Small+med HDL‐P, μmol/L   −5.59±2.24       0.013            −4.11±2.61          0.10            −0.81±3.02     0.79       −2.25±3.42     0.51

Linear regression analyses of small+medium HDL‐P and all other covariates in Table [4](#jah31516-tbl-0004){ref-type="table-wrap"}, association with internal cIMT in the Multi‐Ethnic Study of Atherosclerosis (MESA) study, stratified by race. BMI indicates body mass index; cIMT, carotid intima‐media thickening; HDL‐C, high‐density lipoprotein cholesterol; HDL‐P, high‐density lipoprotein particle concentration; HTN Rx, hypertension medication treatment; LDL‐C, low‐density lipoprotein cholesterol; LLM Rx, lipid‐lowering medication treatment; SBP, systolic blood pressure.

Separate sensitivity analyses were performed for the association of small+medium HDL‐P with common cIMT and internal cIMT across sex (see Table [8](#jah31516-tbl-0008){ref-type="table-wrap"}). After full adjustment, small+medium HDL‐P concentration was consistently associated with decreased common cIMT in men (n=3072; beta coefficient=−2.91 μm and *P*\<0.0001), but not in women (n=3440; beta coefficient=−0.70 μm and *P*=0.15). In contrast, after full adjustment, the opposite pattern was observed with internal cIMT, with women having a significant association of small+medium HDL‐P (n=3381; beta coefficient=−3.89 μm and *P*=0.018), but not men (n=3037; beta coefficient=−3.46 μm, and *P*=0.15; results summarized in Table [8](#jah31516-tbl-0008){ref-type="table-wrap"}). Statistical interaction tests of gender (with females as the reference) and small+medium HDL‐P were conducted on full regression models predicting both common and internal cIMT. The male sex‐by‐small+medium HDL‐P interaction for a full linear regression model of internal cIMT was not significant (*P*=0.69); however, the interaction for common cIMT was significant (*P*=0.0024).

###### 

Sensitivity Analysis by Sex of Association of Small+Medium HDL‐P With Common cIMT and Internal cIMT

  Covariates                Common cIMT, μm (N=6512)   Internal cIMT, μm (N=6418)                                                                       
  ------------------------- -------------------------- ---------------------------- ------------- ---------- --------------- ---------- --------------- ----------
  Age, y                    7.53±0.3−5                 \<0.0001                     6.80±0.30     \<0.0001   16.49±1.15      \<0.0001   15.26±1.02      \<0.0001
  Black, %                  28.59±8.22                 0.00051                      17.03±7.24    0.019      −78.07±27.33    0.0043     −42.64±24.26    0.079
  Hispanic, %               −12.53±8.50                0.14                         −13.67±7.69   0.076      −43.39±28.26    0.12       −100.04±25.75   0.00011
  Asian, %                  −20.03±10.67               0.061                        −24.94±9.70   0.010      −211.51±35.46   \<0.0001   −194.93±32.49   \<0.0001
  BMI, kg/m^2^              5.84±0.81                  \<0.0001                     1.90±0.52     0.00024    3.77±2.69       0.16       0.66±1.73       0.70
  Former smoker, %          12.98±7.67                 0.091                        10.37±7.34    0.16       12.29±25.52     0.63       86.79±24.56     0.00042
  Current smoker, %         13.97±10.86                0.20                         −2.42±10.16   0.81       82.72±36.11     0.022      113.18±34.03    0.00089
  Pack‐years                0.42±0.16                  0.0073                       0.45±0.19     0.022      2.98±0.52       \<0.0001   1.52±0.66       0.021
  SBP, mm Hg                1.55±0.18                  \<0.0001                     1.52±0.13     \<0.0001   3.21±0.59       \<0.0001   2.48±0.45       \<0.0001
  HTN Rx, %                 7.71±7.23                  0.29                         0.85±6.28     0.89       95.93±24.04     \<0.0001   49.24±21.04     0.019
  Fasting glucose, mg/dL    0.010±0.13                 0.94                         0.39±0.14     0.0054     0.45±0.42       0.29       0.55±0.47       0.24
  Diabetes status, %        41.37±12.49                0.00094                      −7.06±12.17   0.56       87.69±41.52     0.035      76.32±40.76     0.061
  LDL‐C, mg/dL              0.61± 0.10                 \<0.0001                     0.30±0.088    0.00062    1.33±0.35       0.00012    0.91±0.29       0.0019
  HDL‐C, mg/dL              −0.41±0.29                 0.16                         −0.61±0.19    0.0019     −0.73±0.98      0.45       −1.54±0.65      0.018
  LLM Rx, %                 24.91±8.88                 0.0050                       18.19±7.78    0.020      106.47±29.51    0.00031    163.67±26.07    \<0.0001
  Small+med HDL‐P, μmol/L   −2.91±0.72                 \<0.0001                     −0.70±0.49    0.15       −3.46±2.40      0.15       −3.89±1.64      0.018

Linear regression analyses of small+medium HDL‐P and all other covariates in Table [4](#jah31516-tbl-0004){ref-type="table-wrap"}, association with common and internal cIMT in the Multi‐Ethnic Study of Atherosclerosis (MESA) study, stratified by sex. BMI indicates body mass index; cIMT, carotid intima‐media thickening; HDL‐C, high‐density lipoprotein cholesterol; HDL‐P, high‐density lipoprotein particle concentration; HTN Rx, hypertension medication treatment; LDL‐C, low‐density lipoprotein cholesterol; LLM Rx, lipid‐lowering medication treatment; SBP, systolic blood pressure.

To determine whether PON1 could potentially mediate the inverse association of small+medium HDL‐P with common and internal cIMT, we performed a follow‐up analysis in the CLEAR study where PON1 measures were available. For this analysis, 126 men without CVD and not taking statins were evaluated for HDL‐P concentrations and PON1 AREase activity. Pearson\'s pair‐wise correlation coefficients were then calculated for each subgroup of HDL‐P and PON1 AREase activity (see Figure [3](#jah31516-fig-0003){ref-type="fig"}). PON1 AREase activity was most strongly correlated with small+medium HDL‐P (*r* ~p~=0.32; *P*=0.00023), followed by total HDL‐P (*r* ~p~=0.27; *P*=0.0024). PON1 AREase activity was not correlated with large HDL‐P (*r* ~p~=0.02; *P*=0.41). Total HDL‐P was strongly correlated with small+medium HDL‐P (*r* ~p~=0.83; *P*\<0.0001) followed by large HDL‐P (*r* ~p~=0.61; *P*\<0.0001).

![Paraoxonase‐1 (PON1) arylesterase hydrolysis activity (AREase) is associated with small and medium high‐density lipoprotein particle concentration (HDL‐P) concentration (*r* ~p~=0.32; *P*=0.00023), but not large HDL‐P concentration (*r* ~p~=0.02; *P*=0.41) in the carotid lesion epidemiology and risk (CLEAR) study (n=126). Cell values reported are Pearson\'s pair‐wise correlation coefficients. \*0.05≤*P*≤0.0001; \*\**P*\<0.0001.](JAH3-5-e002977-g003){#jah31516-fig-0003}

Discussion {#jah31516-sec-0014}
==========

Functional aspects of HDL not reflected by HDL‐C measurements[14](#jah31516-bib-0014){ref-type="ref"}, [15](#jah31516-bib-0015){ref-type="ref"}, [16](#jah31516-bib-0016){ref-type="ref"} may be responsible for the repeated observation that HDL is protective against CVD.[12](#jah31516-bib-0012){ref-type="ref"}, [34](#jah31516-bib-0034){ref-type="ref"}, [35](#jah31516-bib-0035){ref-type="ref"}, [36](#jah31516-bib-0036){ref-type="ref"} In the current work, we present further evidence that small, dense HDL‐P---which is more closely correlated with cardioprotective PON1 activity[25](#jah31516-bib-0025){ref-type="ref"}, [37](#jah31516-bib-0037){ref-type="ref"}---is inversely associated with cIMT. Specifically, we have used linear regression in a large cross‐sectional analysis of ≈6500 MESA participants to demonstrate that cholesterol‐poor small+medium HDL‐P concentration is significantly and inversely associated with common and internal cIMT after adjustment for HDL‐C and other cardiovascular confounders, whereas large HDL‐P was not. Amount of cIMT is positively associated with incident coronary heart disease[38](#jah31516-bib-0038){ref-type="ref"}, [39](#jah31516-bib-0039){ref-type="ref"}; thus, the finding of decreased common and internal cIMT with increasing small+medium HDL‐P is suggestive of possible protection from atherosclerotic end‐organ damage. Finally, using 126 CLEAR participants, we report that PON1 AREase activity is more strongly correlated with small+medium HDL‐P (*r* ~p~=0.32; *P*=0.00023) than large HDL‐P concentration (*r* ~p~=0.02; *P*=0.41).

Large HDL‐P is the cholesterol‐rich subfraction of HDL.[9](#jah31516-bib-0009){ref-type="ref"}, [40](#jah31516-bib-0040){ref-type="ref"} In these data, large HDL‐P is significantly associated with decreased common and internal cIMT after adjustment for a range of covariates. However, the association of large HDL‐P with both common and internal cIMT is attenuated by addition of HDL‐C to the multivariable regression model. In contrast, the association of small+medium HDL‐P was robust to post‐hoc step‐wise addition of HDL‐C to the regression model. These results suggest that HDL‐C is responsible for the inverse correlation between large HDL‐P and both common and internal cIMT, while also demonstrating possible antiatherogenic properties of small+medium HDL‐P that are not fully reflected by HDL‐C measurements alone, as first hypothesized by Kontush and Chapman.[14](#jah31516-bib-0014){ref-type="ref"}, [15](#jah31516-bib-0015){ref-type="ref"}, [16](#jah31516-bib-0016){ref-type="ref"}

Reverse cholesterol transport (RCT), whereby cholesterol is removed from peripheral cells and atherosclerotic plaque,[41](#jah31516-bib-0041){ref-type="ref"}, [42](#jah31516-bib-0042){ref-type="ref"} represents another possible function of HDL that may underlie its cardioprotective effects. A recent study has demonstrated the importance of RCT through direct measurement of macrophage cholesterol efflux capacity in a longitudinal study.[43](#jah31516-bib-0043){ref-type="ref"} In this study, 2924 adults without baseline CVD were followed for a median of 9.4 years, and the highest quartile of cholesterol efflux had a 67% reduction in CVD incidence as compared to the lowest quartile.[43](#jah31516-bib-0043){ref-type="ref"} Notably, cholesterol efflux has an inverse relationship with HDL particle size and density, with the smallest HDL particles having the highest efficiency of cholesterol efflux from macrophage foam cells.[17](#jah31516-bib-0017){ref-type="ref"}

The antioxidant properties of HDL are another function of HDL that may be responsible for its cardioprotection. Past work found that, similar to cholesterol efflux,[17](#jah31516-bib-0017){ref-type="ref"} antioxidant properties of HDL were enriched in the smallest and densest HDL particles.[10](#jah31516-bib-0010){ref-type="ref"} PON1 is a glycoprotein enzyme produced in the liver with extremely broad substrate specificity (for further in‐depth discussion of PON1, please refer to a recent review[44](#jah31516-bib-0044){ref-type="ref"}) that is strongly associated with the smaller/denser HDL particles.[10](#jah31516-bib-0010){ref-type="ref"} Rare mutations in the PON1 gene have previously been reported to be predictive of ischemic stroke.[37](#jah31516-bib-0037){ref-type="ref"} Additionally, PON1 has been shown to prevent in vitro oxidation of LDL[45](#jah31516-bib-0045){ref-type="ref"}, [46](#jah31516-bib-0046){ref-type="ref"}, [47](#jah31516-bib-0047){ref-type="ref"} and HDL.[48](#jah31516-bib-0048){ref-type="ref"} Thus, in this context, our findings that small+medium HDL‐P is strongly associated with decreased common and internal cIMT may, at least in part, reflect the increased cardioprotective enzyme activity of PON1 in these particles[10](#jah31516-bib-0010){ref-type="ref"} as compared to large HDL‐P.

Antiapoptotic and anti‐inflammatory properties of small, dense HDL may also play a role in its protective effects against CVD.[14](#jah31516-bib-0014){ref-type="ref"}, [15](#jah31516-bib-0015){ref-type="ref"}, [16](#jah31516-bib-0016){ref-type="ref"} Recent work in MESA found that small+medium HDL‐P was inversely associated with noncardiovascular inflammation‐related death or hospitalization, suggesting that HDL plays an important role in the pathogenesis of numerous inflammation‐related diseases.[6](#jah31516-bib-0006){ref-type="ref"} In this regard, the HDL content of sphingosine‐1‐phosphate (S1P) and other lipids carried on HDL are important considerations as possible molecular mediators of this anti‐inflammatory effect. S1P is enriched in small and dense HDL[18](#jah31516-bib-0018){ref-type="ref"} and is inversely correlated with endothelial cell apoptosis.[18](#jah31516-bib-0018){ref-type="ref"}, [19](#jah31516-bib-0019){ref-type="ref"} In addition, S1P has been shown to inhibit neutrophil migration and leukocyte adhesion to sites of cellular injury.[49](#jah31516-bib-0049){ref-type="ref"} S1P and other HDL‐related lipids were not measured in MESA, and their effects on cIMT independent of small+medium HDL‐P could not be determined in the current work.

Numerous studies have found that potentially cardioprotective properties increase in potency with decreasing size and density of HDL (ie, antioxidation,[10](#jah31516-bib-0010){ref-type="ref"} anti‐inflammatory effects,[6](#jah31516-bib-0006){ref-type="ref"} cholesterol efflux,[17](#jah31516-bib-0017){ref-type="ref"} and S1P content[18](#jah31516-bib-0018){ref-type="ref"}). To test the possibility that the small+medium HDL‐P association with both common and internal cIMT was driven by small HDL‐P, we performed a post‐hoc analysis including all HDL‐P measures (see Table [6](#jah31516-tbl-0006){ref-type="table-wrap"}). We found that both small and medium HDL‐P were independently and significantly associated with common and internal cIMT. Further investigation in other longitudinal studies with HDL‐P measures is required to determine whether either of small or medium HDL‐P is more strongly associated with decreased cardiovascular disease incidence.

Sensitivity analyses of the relationship of small+medium HDL‐P with common and internal cIMT measures across racial groups have limited power. Notably, the direction of the relationship of the HDL measures with both common and internal cIMT is negative across all racial groups and both sex groups, if not always statistically significant. However, we note that Asians and women have a near‐zero association of small+medium HDL and common CIMT. In addition, Hispanics had an attenuated beta coefficient and nonsignificant association between small+medium HDL‐P and internal cIMT. Though a formal interaction test was not significant for effect modification by race group (including Asians) of small+medium HDL‐P association with either common or internal cIMT, we did note a significant interaction between male sex and small+medium HDL‐P for the association with common cIMT. Notably, work by Mackey et al., analyzing 5597 overlapping participants from this current work, did not find evidence of effect modification by sex or race for total HDL‐P or HDL‐C and cIMT measures.[5](#jah31516-bib-0005){ref-type="ref"} Further work is required to elucidate whether these findings represent true population differences in associations of small+medium HDL‐P concentration, or whether they result from random population variance.

Limitations of this study should be considered. First, this study is cross‐sectional and observational. Second, these results imply that unmeasured functional aspects of small+medium HDL‐P are at least partially responsible for the HDL‐C independent and inverse association of small+medium HDL‐P and carotid atherosclerosis. However, with the current data, it is not currently possible to distinguish whether the effects are attributed to PON1 or other antioxidant protein activity, RCT, S1P, or other molecule‐associated anti‐inflammatory and antiapoptotic properties, or possibly other HDL‐related functions.[15](#jah31516-bib-0015){ref-type="ref"} Similarly, PON1 enzyme activity requires calcium ions for proper function. Therefore, plasma stored with EDTA or other calcium‐chelating agents cannot be measured for their PON1 activity; consequently, PON1 activity could not be measured in the MESA cohort. Finally, several variables with importance to CVD in general and HDL in particular (eg, S1P) were not available and thus could not be included in analyses. Strengths of this study include its multiethnic and sex‐balanced design, which allow for greater sex‐ and genetic ancestry--specific generalizations regarding the associations of HDL‐P subclasses with cIMT outcomes.

In summary, we have performed analyses on participants in the large, well‐characterized MESA cohort and report that small+medium HDL‐P is strongly and inversely associated with cIMT in both the common and internal carotid arteries. Large HDL‐P is not associated with cIMT in either carotid artery branch after adjustment for HDL‐C, suggesting that cholesterol carried by HDL is likely not important in prevention of cardiovascular and cerebrovascular disease. Finally, we report, from separate data in the CLEAR study, that cardioprotective PON1 AREase activity is most strongly correlated with small+medium HDL‐P, as compared to both total HDL‐P and large HDL‐P measures. Future work should evaluate the specific functional aspects of HDL, including PON1 activity, to identify biomarkers for clinical intervention.
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